Fig. 2

CMV DNA positivity affects subpopulations of CD56^Lo NK cells. Proportions of CD56^Lo NK cells trended higher in CMV DNA+ group (A). FcRγ⁻ (FcRεγ⁻) CD56^Lo NK cells were lowest in CMV DNA+ patients at V0 and improved after 6 months of ART (B). Proportions of NKG2C⁺ and CD57⁺ NK cells increased on ART in CMV DNA+ patients (C, D). Proportions of LIR1⁺ NK cells were similar in patients with and without CMV DNA (E). Proportions of CD16⁺ CD56^Lo NK cells at V6 were higher in CMV DNA+ patients (F). Mann–Whitney tests were used to compare patients with and without detectable CMV DNA at V0. Wilcoxon tests were used to compare patients at V0 and V6. Vertical lines depict 95% confidence interval of the median, boxes represent the interquartile range and horizontal lines mark the median. *p < 0.05 and **p < 0.01